These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

459 related articles for article (PubMed ID: 34595949)

  • 1. Health care utilization and costs associated with direct-acting antivirals for patients with substance use disorders and chronic hepatitis C.
    Jiang X; Vouri SM; Diaby V; Lo-Ciganic W; Parker R; Park H
    J Manag Care Spec Pharm; 2021 Oct; 27(10):1388-1402. PubMed ID: 34595949
    [No Abstract]   [Full Text] [Related]  

  • 2. The use of all-oral direct-acting antivirals in hepatitis C virus-infected patients with substance use disorders.
    Jiang X; Song HJ; Wang W; Henry L; Childs-Kean LM; Re VL; Park H
    J Manag Care Spec Pharm; 2021 Jul; 27(7):873-881. PubMed ID: 34185563
    [No Abstract]   [Full Text] [Related]  

  • 3. Racial/Ethnic and Socioeconomic Disparities in Use of Direct-Acting Antivirals Among Medicare Beneficiaries with Chronic Hepatitis C, 2014-2016.
    Jung J; Du P; Feldman R; Kong L; Riley T
    J Manag Care Spec Pharm; 2019 Nov; 25(11):1236-1242. PubMed ID: 31663464
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Direct-Acting Antiviral Treatment Use Remains Low Among Florida Medicaid Beneficiaries With Chronic Hepatitis C.
    Park H; Song HJ; Jiang X; Henry L; Cook RL; Nelson DR
    Hepatol Commun; 2021 Feb; 5(2):203-216. PubMed ID: 33553969
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The Impact of Direct-Acting Antiviral Therapy on End-Stage Liver Disease Among Individuals with Chronic Hepatitis C and Substance Use Disorders.
    Park H; Jiang X; Song HJ; Lo Re V; Childs-Kean LM; Lo-Ciganic WH; Cook RL; Nelson DR
    Hepatology; 2021 Aug; 74(2):566-581. PubMed ID: 33544904
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Has Access to Hepatitis C Virus Therapy Changed for Patients With Mental Health or Substance Use Disorders in the Direct-Acting-Antiviral Period?
    Jain MK; Thamer M; Therapondos G; Shiffman ML; Kshirsagar O; Clark C; Wong RJ
    Hepatology; 2019 Jan; 69(1):51-63. PubMed ID: 30019478
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Economic impact of applying the AASLD-IDSA simplified treatment algorithm on the real-world management of hepatitis C.
    Majethia S; Lee IH; Chastek B; Bunner S; Wolf J; Hsiao A; Mozaffari E
    J Manag Care Spec Pharm; 2022 Jan; 28(1):48-57. PubMed ID: 34677088
    [No Abstract]   [Full Text] [Related]  

  • 8. Impact of All-Oral Direct-Acting Antivirals on Clinical and Economic Outcomes in Patients With Chronic Hepatitis C in the United States.
    Park H; Wang W; Henry L; Nelson DR
    Hepatology; 2019 Mar; 69(3):1032-1045. PubMed ID: 30289989
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Early Treatment Uptake and Cost Burden of Hepatitis C Therapies Among Newly Diagnosed Hepatitis C Patients with a Particular Focus on HIV Coinfection.
    van Boemmel-Wegmann S; Lo Re V; Park H
    Dig Dis Sci; 2020 Nov; 65(11):3159-3174. PubMed ID: 31938995
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A real-world observational study of drug utilization and clinical outcomes of direct-acting antivirals and interferon therapy for hepatitis C treatment in Taiwan.
    Chen JH; Wu PN; Huang SC; Hsu PJ; Hsu JC
    Curr Med Res Opin; 2021 Feb; 37(2):245-252. PubMed ID: 33251875
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Association of Direct-Acting Antiviral Therapy for Hepatitis C With After-Treatment Costs Among Medicare Beneficiaries.
    Jung J; Feldman R; Kalidindi Y; Riley T
    JAMA Netw Open; 2020 Jun; 3(6):e208081. PubMed ID: 32602909
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Impact of Substance Use Disorder on the Rate of Sustained Virological Response in Veterans With Chronic Hepatitis C Treated With Direct-Acting Antivirals.
    Ottman AA; Townsend ML; Hashem MG; Britt RB
    Ann Pharmacother; 2019 Jun; 53(6):581-587. PubMed ID: 30654625
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Association of Direct-Acting Antiviral Treatment With Mortality Among Medicare Beneficiaries With Hepatitis C.
    Kalidindi Y; Jung J; Feldman R; Riley T
    JAMA Netw Open; 2020 Jul; 3(7):e2011055. PubMed ID: 32692371
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of relaxing hepatitis C treatment restrictions on direct-acting antiviral use in a Medicaid program: an interrupted time series analysis.
    Herink MC; Geddes J; Vo K; Zaman A; Hartung DM
    J Manag Care Spec Pharm; 2021 Jul; 27(7):856-864. PubMed ID: 34185560
    [No Abstract]   [Full Text] [Related]  

  • 15. Cost-effectiveness of direct-acting antivirals for chronic hepatitis C virus in the United States from a payer perspective.
    Kaplan DE; Serper M; Kaushik A; Durkin C; Raad A; El-Moustaid F; Smith N; Yehoshua A
    J Manag Care Spec Pharm; 2022 Oct; 28(10):1138-1148. PubMed ID: 36125059
    [No Abstract]   [Full Text] [Related]  

  • 16. Declining hepatitis C virus-related liver disease burden in the direct-acting antiviral therapy era in New South Wales, Australia.
    Alavi M; Law MG; Valerio H; Grebely J; Amin J; Hajarizadeh B; Selvey C; George J; Dore GJ
    J Hepatol; 2019 Aug; 71(2):281-288. PubMed ID: 31078544
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Treatment patterns, health care resource utilization, and costs in U.S. patients diagnosed with chronic hepatitis C infection who received telaprevir or boceprevir.
    Le TK; Kalsekar A; Macaulay D; Yuan Y; Sorg RA; Behrer CR; Wei J; Wu EQ
    J Manag Care Spec Pharm; 2015 Apr; 21(4):308-18. PubMed ID: 25803764
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Real-world treatment for chronic hepatitis C infection in Germany: Analyses from drug prescription data, 2010-2015.
    Zimmermann R; Kollan C; Ingiliz P; Mauss S; Schmidt D; Bremer V
    J Hepatol; 2017 Jul; 67(1):15-22. PubMed ID: 28189752
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Disparities in Initiation of Direct-Acting Antiviral Agents for Hepatitis C Virus Infection in an Insured Population.
    Marcus JL; Hurley LB; Chamberland S; Champsi JH; Gittleman LC; Korn DG; Lai JB; Lam JO; Pauly MP; Quesenberry CP; Ready J; Saxena V; Seo SI; Witt DJ; Silverberg MJ
    Public Health Rep; 2018; 133(4):452-460. PubMed ID: 29750893
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Does Hepatitis C Treatment Adherence Affect Risk of Liver Transplantation? A Historical Cohort Study.
    Ems D; Racsa P; Anderson C; Gregory F; Worley K; Brill JV; Holt W
    J Manag Care Spec Pharm; 2016 Jul; 22(7):863-71. PubMed ID: 27348286
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.